Afamelanotide

Scenesse / Melanotan ISkin/Hair

Evidence grade

AFDA-approved Rx (labeled use)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeSkin / Photoprotection

MechanismMelanocortin-1 receptor agonist; increases eumelanin to raise the skin’s tolerance of light

EffectsRaises light tolerance in a rare photosensitivity disorder; distinct from Melanotan II, which is unapproved

Dosing16 mg subcutaneous implant every 2 months

Bottom lineStrongest data when used for its labeled indication under clinician guidance.

Batches on filenone

No tested batches on file.

Read with10

GHK-Cu (Copper peptide)Semaglutide Tirzepatide Liraglutide Exenatide Dulaglutide Pramlintide Cagrilintide Retatrutide Leptin / Metreleptin

Cautions & interactions

Implant-site reactions; darkening of skin and moles requires skin monitoring; not a tanning product

Follow the prescribing information; regular full-body skin examination is required.

CV 1 of 5 — No meaningful cardiovascular signal at the labelled dose; unlike Melanotan II it is MC1R-selective.